FOR BLADDER SYNDROMES
Our drug candidates are locally applied treatments for common bladder disorders. Our most advanced product, LP-08, targets interstitial cystitis—a painful, chronic inflammation of the bladder that afflicts an estimated 3.3M to 7.9M Americans.
By limiting drug distribution to the bladder, our products minimize the risk of the adverse effects that accompany traditional therapies.
Working with well-known active agents, they significantly boost the potential for therapeutic efficacy.
A clinical-stage product for interstitial cystitis (IC). An “empty” liposome product, LP-08 has proven effective in clinical trials of patients with IC, showing significant efficacy with minimal side-effects.
A clinical-stage product for overactive bladder (OAB) that has shown marked reduction in urinary frequency and urinary urgency for patients with OAB, without the common side-effects associated with orally administered drugs.
A liposomal formulation of tacrolimus, a potent immunosuppressant that also has strong anti-inflammatory effects. Lipella received orphan designation from the US FDA for the use of tacrolimus for the treatment of hemorrhagic cystitis.